Part 12/13:

While Singapore and Hong Kong’s experiences with Sinovac are generally positive, global data shows mixed results concerning its effectiveness against newer variants like Delta and Omicron. Countries such as Indonesia and Indonesia are also grappling with breakthrough cases, prompting adjustments in vaccination policies.

The ongoing collection of real-world data, combined with laboratory studies, will inform future strategies, including booster doses, vaccine pairing options, and potential updates to formulations tailored for emerging variants.